Zai Lab Shares Slip Despite Positive Early Trial Data for Eczema Drug Candidate

Shares of Zai Lab Limited dropped 6.84% to trade at $24.26 following the release of early-stage clinical trial findings for ZL-1503, an experimental bispecific antibody designed to treat moderate-to-severe atopic dermatitis. For everyday investors tracking biotech pipelines, the initial data offers a glimpse into potential long-acting therapies for chronic inflammatory skin conditions.

According to the company, findings from 48 healthy participants in a randomized, double-blind study demonstrated that a single dose of 200 mg or greater blocked the IL-13 signaling biomarker by at least 90% through the twelfth week. The treatment also reduced other inflammatory indicators, including TARC, CCL26, and IgE levels, across tested doses ranging from 50 mg to 1,000 mg.

Pharmacokinetic evaluations highlighted an extended half-life spanning approximately 40 to 50 days, nearly doubling the duration of several currently approved biologics. This profile supports the possibility of a quarterly maintenance schedule. Furthermore, investigators reported no serious adverse events or dose-limiting toxicities during the trial period.

What to watch next: Zai Lab anticipates reporting cohort data from the second part of the trial in the first half of 2027, alongside results from an intravenous-to-subcutaneous bioavailability bridging study.